Health Canada and the Public Health Agency of Canada have been monitoring this condition since it was raised as a potential safety concern by the European Medicines Agency in April, the statement added. Until June 11, one case of capillary leak syndrome following vaccination with AstraZeneca's vaccine has been reported in Canada, Health Canada said. Earlier this month, the European Medicines Agency's safety committee said that capillary leak syndrome must be added as a new side effect to labeling on AstraZeneca's vaccine, known as Vaxzevria. Britain's regulator, the MHRA, has previously said it was considering precautionary advice for people with a history of CLS but does not see a causal link with the vaccine. (Reporting by Kanishka Singh in Bengaluru; Editing by Raju Gopalakrishnan)